Medla https://www.medla.com.au/podcast en Medla works on behalf of some of the significant international societies and congresses to bring you a series of officially licensed events and programs in oncology. These include ASCO, ESMO and SABCS. On top of live events and videos, these podcasts provide another opportunity to catch up with critical updates - when and wherever you choose to. You can expect thorough and informed discussions between experts in their field, who will leave you with their perspectives on emerging options for you to offer your patients. In the first series of podcasts, A/Prof Ben Tran and Prof Lisa Horvath discuss prostate cancer and their takeouts from ASCO 2023. https://megaphone.imgix.net/podcasts/e73f960e-479d-11ee-afd7-7f5f9ae27728/image/MedlaTitleImage.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Medla https://www.medla.com.au/podcast no episodic Medla Medla works on behalf of some of the significant international societies and congresses to bring you a series of officially licensed events and programs in oncology. These include ASCO, ESMO and SABCS. On top of live events and videos, these podcasts provide another opportunity to catch up with critical updates - when and wherever you choose to. You can expect thorough and informed discussions between experts in their field, who will leave you with their perspectives on emerging options for you to offer your patients. In the first series of podcasts, A/Prof Ben Tran and Prof Lisa Horvath discuss prostate cancer and their takeouts from ASCO 2023. Medla works on behalf of some of the significant international societies and congresses to bring you a series of officially licensed events and programs in oncology. These include ASCO, ESMO and SABCS.

On top of live events and videos, these podcasts provide another opportunity to catch up with critical updates - when and wherever you choose to.

You can expect thorough and informed discussions between experts in their field, who will leave you with their perspectives on emerging options for you to offer your patients.

In the first series of podcasts, A/Prof Ben Tran and Prof Lisa Horvath discuss prostate cancer and their takeouts from ASCO 2023.

]]> Medla dan@afternoonsport.com Episode 3 - PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer. PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer. Thu, 31 Aug 2023 01:35:20 -0000 full 3 Medla PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer. PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.

]]> 902 Episode 2 - Prostate cancer and Artificial Intelligence. Where does AI sit with prostate cancer now and beyond? Prostate cancer and Artificial Intelligence. Where does AI sit with prostate cancer now and beyond? Thu, 31 Aug 2023 01:34:30 -0000 full 2 Medla Prostate cancer and Artificial Intelligence. Where does AI sit with prostate cancer now and beyond? Prostate cancer and Artificial Intelligence. Where does AI sit with prostate cancer now and beyond?

]]> 755 Episode 1 - Immuno-oncology in prostate cancer. Amid all the excitement for immunotherapies in other major tumour types, what is the outlook for prostate cancer? Immuno-oncology in prostate cancer. Amid all the excitement for immunotherapies in other major tumour types, what is the outlook for prostate cancer? Thu, 31 Aug 2023 01:32:13 -0000 full 1 Medla Immuno-oncology in prostate cancer. Amid all the excitement for immunotherapies in other major tumour types, what is the outlook for prostate cancer? Immuno-oncology in prostate cancer. Amid all the excitement for immunotherapies in other major tumour types, what is the outlook for prostate cancer?

]]> 1487